Early trial tests new drug cocktail for rare, debilitating protein disease

This early-stage study is testing the safety and best doses of a three-drug combination (daratumumab, ixazomib, and dexamethasone) for people with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if this combination can control the disease by targeting the cells that make the harmful proteins. The study will enroll about 21 adults with newly diagnosed or returning disease to find the safest, most effective dose for future testing.